Indication
Chronic indeterminate Chagas disease
Chronic indeterminate Chagas disease is the latent, subclinical stage of persistent infection caused by the protozoan parasite *Trypanosoma cruzi*. Read more about Chronic indeterminate Chagas disease
1 drugs 1 manufacturers
Drugs that treat it
Common Chronic indeterminate Chagas disease therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic indeterminate Chagas disease is the latent, subclinical stage of persistent infection caused by the protozoan parasite *Trypanosoma cruzi*.
It primarily affects infected pediatric and adult populations without overt clinical illness, representing the majority of chronic cases following the resolution of the acute phase.
Pathophysiologically, low-level intracellular parasite persistence and a host immune equilibrium characterize this state.
Clinically, it is defined by reactive serological testing for *T.
cruzi* antibodies alongside a total absence of clinical symptoms, normal electrocardiographic findings, and no evidence of cardiac, gastrointestinal, or autonomic organ damage.
- cdc.gov
Chronic indeterminate Chagas disease is the latent, subclinical stage of persistent infection caused by the protozoan parasite *Trypanosoma cruzi*
- nih.gov
Chronic indeterminate Chagas disease is the latent, subclinical stage of persistent infection caused by the protozoan parasite *Trypanosoma cruzi*
- texas.gov
Chronic indeterminate Chagas disease is the latent, subclinical stage of persistent infection caused by the protozoan parasite *Trypanosoma cruzi*
- nih.gov
It primarily affects infected pediatric and adult populations without overt clinical illness, representing the majority of chronic cases following the resolution of the acute phase
- nih.gov
It primarily affects infected pediatric and adult populations without overt clinical illness, representing the majority of chronic cases following the resolution of the acute phase Clinically, it is defined by reactive serological testing for *T. cruzi* antibodies alongside a total absence of clinical symptoms, normal electrocardiographic findings, and no evidence of cardiac, gastrointestinal, or autonomic organ damage
- nih.gov
Pathophysiologically, low-level intracellular parasite persistence and a host immune equilibrium characterize this state
- coreem.net
Pathophysiologically, low-level intracellular parasite persistence and a host immune equilibrium characterize this state
- nih.gov
Clinically, it is defined by reactive serological testing for *T. cruzi* antibodies alongside a total absence of clinical symptoms, normal electrocardiographic findings, and no evidence of cardiac, gastrointestinal, or autonomic organ damage
Personalize your experience
Follow Chronic indeterminate Chagas disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.